Lucid Net Tangible Assets from 2010 to 2026
| LUCD Stock | USD 1.45 0.04 2.84% |
Net Tangible Assets | First Reported 2010-12-31 | Previous Quarter 22.5 M | Current Value 23.7 M | Quarterly Volatility 13.4 M |
Macro event markers
Review Lucid Diagnostics financial statements over time to add context on performance and capital structure. Track Depreciation And Amortization of 997.8 K, Interest Expense of 28.4 K or Selling General Administrative of 24.3 B and ratios such as Price To Sales Ratio of 10.4, Dividend Yield of 0.0 or PTB Ratio of 7.25 to align performance context with Lucid Diagnostics Valuation and Volatility.
Lucid | Net Tangible Assets | Build AI portfolio with Lucid Stock |
Analyzing Lucid Diagnostics's Net Tangible Assets over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Tangible Assets has evolved provides context for assessing Lucid Diagnostics's current valuation and future prospects.
Latest Lucid Diagnostics' Net Tangible Assets Growth Pattern
Below is the plot of the Net Tangible Assets of Lucid Diagnostics over the last few years. It is the total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. Lucid Diagnostics' Net Tangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lucid Diagnostics' overall financial position and show how it may be relating to other accounts over time.
| Net Tangible Assets | 10 Years Trend |
|
Net Tangible Assets |
| Timeline |
Lucid Net Tangible Assets Regression Statistics
| Arithmetic Mean | 3,087,751 | |
| Geometric Mean | 3,917,050 | |
| Coefficient Of Variation | 433.19 | |
| Mean Deviation | 10,538,701 | |
| Median | -1,062,681 | |
| Standard Deviation | 13,375,787 | |
| Sample Variance | 178.9T | |
| Range | 47.8M | |
| R-Value | 0.53 | |
| Mean Square Error | 136.9T | |
| R-Squared | 0.28 | |
| Significance | 0.03 | |
| Slope | 1,408,552 | |
| Total Sum of Squares | 2862.6T |
Lucid Net Tangible Assets History
About Lucid Diagnostics Inc
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. A high-level view of Lucid Diagnostics emphasizes earnings durability, balance-sheet flexibility, and competitive positioning. Current metrics include P/B of 2.16. Lucid Diagnostics has market cap of 191.4 M, ROE of -3.31%.
Methodology
Unless otherwise specified, financial data for Lucid Diagnostics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Lucid (USA Stocks:LUCD) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: We use public filings and market reference sources with disclosures published by U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Food & Drug Administration (FDA) as reference inputs. Data may be normalized and can be delayed. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Lucid Diagnostics may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.More Resources for Lucid Stock Analysis
A structured review of Lucid Diagnostics often starts with core financial statements and trend context. Financial ratios provide context for profitability, efficiency, and growth trends. Below are reports that help frame Lucid Diagnostics Stock in context:Review Lucid Diagnostics Correlation against competitors for Lucid Diagnostics. The view adds relative comparison context. For more information on how to buy Lucid Stock please use our How to Buy Lucid Stock guide.Analysis related to Lucid Diagnostics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Earnings Share -0.77 | Revenue Per Share | Quarterly Revenue Growth 0.033 | Return On Assets | Return On Equity |
The market value of Lucid Diagnostics is measured differently than book value, which reflects Lucid accounting equity. Lucid Diagnostics' market capitalization is 191.4 M. A P/B ratio of 2.16 indicates the market values Lucid Diagnostics above its accounting book value. Enterprise value stands at 222.68 M. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Valuation work aligns these measures into a single context.
Note that Lucid Diagnostics' intrinsic value and market price are different measures derived from different inputs. For Lucid Diagnostics, key inputs include a P/B ratio of 2.16, ROE of -3.31%, and revenue of 4.35 M. Trading price represents the transaction level agreed by market participants.